Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland

ECDC comment

10 October 2011

Rotavirus gastroenteritis in Ireland is a quite common and unpleasant illness, but severe disease is unusual and death extremely rare. Nonetheless, rotavirus generates considerable direct and indirect costs.

Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, Barry M. Vaccine. 2011 Oct 6;29(43):7463-73.

Although vaccines currently available are safe and efficacious, the option of universal vaccination coverage is too costly in Ireland under the base case assumptions. However, future vaccine price reductions, e.g. following competitive tendering, might lead to reconsider the issue.

Related content

Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Pre-Term European Infants: A Randomized Phase IIIb Study Archived

1 February 2012

Impact of rotavirus vaccination on epidemiological dynamics in England and Wales Archived

9 December 2011

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial Archived

14 September 2011

Share this page